Skip to main content

RT @uptoTate: Phase 1 data shows Ebdarokimab (IL12/23i) safe and well tolerated in moderate to severe plaque psoriasis p

Social Author Name
Dr. Rachel Tate
Tweet Content
Phase 1 data shows Ebdarokimab (IL12/23i) safe and well tolerated in moderate to severe plaque psoriasis patients. Abs 0752 #ACR22 @RheumNow https://t.co/QqTE4WJtDa https://t.co/eMaEurZAr0
Show on Archive Page
On
Display in Search Results
On
PDQ
Off